Analysts predict continued double-digit growth for the GLP-1/metabolic disease market, driven by global obesity trends and more indications
Global Weight-Loss Deal Activity in 2025 H1: Partnerships and New Drug Investments In H1 2025, the weight-loss sector and metabolic diseases saw a flurry of dealmaking
Insurance coverage and cost are also important considerations in medication selection
We began the experiment at approximately 1:30 in the afternoon Photo by Innerbody Research and before the 30-minute point, we saw that the beetroot capsule had begun to warp and blister while Pendulum remained unchanged
This includes people taking insulin or sulfonylureas, patients with diabetes, patients on blood pressure medications, patients with kidney disease or dehydration risk, patients with a gallbladder history, patients with significant reflux or gastroparesis symptoms, patients with eating disorder history, and patients who have difficulty meeting protein or fluid needs
Recent antibiotic use combined with GLP-1 therapy may increase the risk of digestive disturbances and should be mentioned to your healthcare provider
